Resultados de Búsqueda

Evidencias COVID-19

IHCAI – DIME. Información seleccionada sobre intervenciones para el tratamiento de COVID-19

A cohort study was conducted to find out if Ivermectin has effects on the outcomes of COVID-19. Although we report a strong potential signal for benefit in COVID-19, these data must not be considered conclusive since unknown confounders cannot always be reliably accounted for, even when propensity score matching techniques are emplooyed in developing control groups. There is no substitute to a properly conducted randomized clinical trial. However, ass the tempo of COVID-19 rages and ...

Evidencias COVID-19

IHCAI – DIME. Información seleccionada sobre intervenciones para el tratamiento de COVID-19

Despite limited and conflicting data on the use of hydroxychloroquine in patients with Covid-19, the U.S. Food and Drug Administration has authorized the emergency use of this drug when clinical trials are unavailable or infeasible. Hydroxychloroquine, alone or in combination with azithromycin, is being widely used in Covid-19 therapy based on anecdotal and limited observational evidence. In this study, we found no evidence that use of hydroxychloroquine, either with or without azithromycin, ...

Evidencias COVID-19

IHCAI – DIME. Información seleccionada sobre intervenciones para el tratamiento de COVID-19

Although there are clinical opinions in favor of the prophylactic use of Chloroquine (CQ) and Hydroxychloroquine (HCQ) against COVID-19, there are no original clinical studies on the prophylactic role of CQ or HCQ in COVID-19. Furthermore, although the preclinical results are promising, to date there is a paucity of evidence to support the efficacy of CQ or HCQ in the prevention of COVID-19. Considering potential safety concerns and the likelihood of imparting a false sense of safety, CQ or HCQ ...

Evidencias COVID-19

IHCAI – DIME. Información seleccionada sobre intervenciones para el tratamiento de COVID-19

This systematic review evaluated the safety and efficacy of Hydroxychloroquine, alone or in combination with other medications. In terms of clinical cure, two studies reported a potential benefit in "normalizing body temperature" and another study reported fewer "days of cough" in the HCQ arm. HCQ treatment resulted in fewer cases showing the radiological progression of lung disease. No difference in virological cure, death or clinical worsening of disease, or safety was observed compared to ...

Evidencias COVID-19

IHCAI – DIME. Información seleccionada sobre intervenciones para el tratamiento de COVID-19

In a retrospective observational cohort study conducted in France, individuals with SARS-CoV-2 RNA documented by PCR from a nasopharyngeal sample were offered early treatment with Hydroxychloroquine plus Azithromycin (HCQ + AZ), independently, as standard care. whether they had symptoms or not. Such treatment was found to reduce viral load and all deaths resulted from respiratory failure and not cardiac toxicity. Adverse clinical outcomes were associated with increased age, severity on ...